Advertisement

Clinical Drug Investigation

, Volume 23, Issue 1, pp 55–62 | Cite as

Comparison of the Efficacy of Nebulised Budesonide with Parenteral Corticosteroids in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease

  • A. Mirici
  • M. Meral
  • M. AkgunEmail author
Original Research Article

Abstract

Objective

To compare the efficacy and safety of nebulised budesonide and systemic corticosteroid in the treatment of acute exacerbations of chronic obstructive pulmonary disease (COPD).

Design

Randomised, double-blind, placebo-controlled, parallel-group trial.

Patients and interventions

A total of 40 patients who had moderate to severe acute exacerbations of COPD and required hospitalisation were enrolled in the study. The patients were randomised to receive either nebulised budesonide 8mg daily (n = 21) or systemic (intravenous) prednisolone 40mg daily (n = 19). Airway obstruction (peak expiratory flow rate [PEFR]) and gas exchange (arterial partial pressure of oxygen [PaO2] and carbon dioxide [PaCO2], pH and oxygen saturation [SaO2]) were evaluated at 30 min, at 6, 24 and 48 hours, and at day 10.

Results

There were no significant differences between groups at baseline. In both groups, differences were significant for PEFR, SaO2 and PaO2 (p < 0.001), but not for PaCO2 and pH, in comparison with their baseline values. There were no significant differences between groups for all parameters (PEFR, PaO2, PaCO2, pH and SaO2) at all time periods. No adverse events were recorded in either group.

Conclusions

Our study suggests that nebulised budesonide may be an alternative to parenteral corticosteroids in the treatment of acute exacerbations of COPD.

Keywords

Chronic Obstructive Pulmonary Disease Budesonide Acute Exacerbation Systemic Corticosteroid Peak Expiratory Flow Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The authors have provided no information on sources of funding or on conflicts of interest directly relevant to the content of this study.

References

  1. 1.
    Turkish Thoracic Society -COPD Study Group. The national guidelines to diagnosis and treatment of chronic obstructive pulmonary disease [in Turkish]. Toraks Dergisi 2000; 1 Suppl. 2: 1–25Google Scholar
  2. 2.
    National Heart, Lung, and Blood Institute. Global initiative for chronic obstructive lung disease. NHLBI Workshop Report 2701; 2001 Apr, Chapter 4Google Scholar
  3. 3.
    ATS Statement. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: 78–83CrossRefGoogle Scholar
  4. 4.
    Jeffery PK. Pathology of asthma and COPD. Eur Respir Rev 1997; 7(43): 111–8Google Scholar
  5. 5.
    Fabbri LM, Durham S, Holgate ST, et al. Assessment of airway inflammation: an overview. Eur Respir J Suppl 1998 Mar; 26: 6S–8SPubMedGoogle Scholar
  6. 6.
    National Heart, Lung, and Blood Institute. Global Initiative for Asthma. NHLBI/WHO Workshop Report 2002. NIH Publication No: 02-3659. Available from URL: http//www. ginasthma.com/ [Accessed 2002 Jun 10]Google Scholar
  7. 7.
    Turkish Thoracic Society — Asthma Study Group. The national guideline of diagnosis and treatment of asthma [in Turkish]. Toraks Dergisi 2000; 1 Suppl. 1: 1–32Google Scholar
  8. 8.
    Mirici A, Bektas Y, Ozbakis G, et al. Effect of inhaled cortico-steroids on respiratory function tests and airway inflammation in stable chronic obstructive pulmonary disease. Clin Drug Invest 2001; 21(12): 835–42CrossRefGoogle Scholar
  9. 9.
    Posthma DS, Kerstjens HAM. Are inhaled glucocorticosteroids effective in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 1999; 160: 66–71CrossRefGoogle Scholar
  10. 10.
    Niewoehner D, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999; 340: 1941–7CrossRefPubMedGoogle Scholar
  11. 11.
    Sayiner A, Aytemur ZA, Cirit M, et al. Systemic glucocorticosteroids in severe exacerbations of COPD. Chest 2001; 119: 726–30CrossRefPubMedGoogle Scholar
  12. 12.
    Westbroek J, Saarelainen S, Laher M, et al. Oral steroid-sparing effect of two doses of nebulized fluticasone propionate and placebo in patients with severe chronic asthma. Respir Med 1999; 93: 689–99CrossRefPubMedGoogle Scholar
  13. 13.
    Winter JH, Dhillon BP, Winter JE, et al. Effect of the early substitution of nebulized fluticasone proprionate 2mg bid for oral prednisolone 50mg in adults during the early recovery period of an acute exacerbation. Eur Respir J 1997; 25(Suppl): 174sGoogle Scholar
  14. 14.
    Saetta M. Airway pathology of COPD compared with asthma. Eur Respir Rev 1997; 7(45): 211–5Google Scholar
  15. 15.
    Calverley PMA, Rennard S, Agusti AGN, et al. Current and future management of acute exacerbations of chronic obstructive pulmonary disease. Eur Respir Rev 1999; 9(67): 193–205Google Scholar
  16. 16.
    Morice AH, Morris D, Lawson-Matthew P. A comparison of nebulized budesonide with oral prednisolone in the treatment of exacerbations of obstructive pulmonary disease. Clin Pharmacol Ther 1996 Dec; 60(6): 675–8CrossRefPubMedGoogle Scholar
  17. 17.
    Maltais F, Ostinelli J, Bourbeau J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002 Mar 1; 165(5): 698–703CrossRefPubMedGoogle Scholar
  18. 18.
    Albert RK, Martin TR, Lewis SW. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory failure. Ann Intern Med 1980; 92: 753–8CrossRefPubMedGoogle Scholar
  19. 19.
    Thompson WH, Nielson CP, Carvalbo P, et al. Controlled trial of oral prednisolone in outpatients with COPD exacerbation. Am J Respir Crit Care Med 19961154: 407-12Google Scholar
  20. 20.
    Murata GH, Gorby MS, Chick TW. Intravenous and oral corticosteroids for the prevention of relapse after treatment of decompensated COPD: effects on patients with a history of multiple relapses. Chest 2000; 98: 845–9CrossRefGoogle Scholar
  21. 21.
    Rubini F, Rampulla C, Nava S. Acute effect of corticosteroids on respiratory mechanics in mechanically ventilated patients with chronic airflow obstruction and acute respiratory failure. Am J Respir Crit Care Med 1994; 149: 306–10CrossRefPubMedGoogle Scholar
  22. 22.
    Decramer M, Stas K. Corticosteroid-induced myopathy involving respiratory muscles in patients with COPD and asthma. Am Rev Respir Dis 1992; 146: 800–2CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2003

Authors and Affiliations

  1. 1.Aziziye Arastirma Hastanesi, Gogus HastaliklariAtatürk UniversitesiErzurumTurkey

Personalised recommendations